Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

By T. Sørlie, Charles M. Perou, Robert Tibshirani, T. Aas, S. Geisler, H. Johnsen, Trevor J. Hastie, Michael B. Eisen, M. van de Rijn, S. Jeffrey and 7 more. Proceedings of the National Academy of Sciences of the United States of America, 2001

11,522 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/2a0bf30dc789b2f9aa9f1078cff496afe54134e2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

Citations in the corpus

Gastric Adenocarcinoma: Review and Considerations for Future Directions (2005, positive): “Lymph node status, receptor status, proto-oncogenes, and gene mutations have all been correlated to prognosis in breast cancer.(131) However, breast cancer is complex, and knowledge about individual prognostic factors provides limited information about the biology of breast cancer.”
Epidemiology of basal-like breast cancer (2008, background): “Perou and colleagues [2–4] further characterized “basal-like” breast cancer as one of five principal subtypes identified in a supervised gene expression analysis of breast tumors.”
An overview of triple-negative breast cancer (2016, background): “TNBC is an aggressive phenotype, carries a poorer prognosis than the luminal tumors [6, 7, 15, 16] and represents a consistent subgroup of breast cancers with heterogeneous clinical presentation, behavior, pathology and response to treatment [22].”
Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? (2005, background): “of so-called ‘‘basal markers’’ identified by gene array studies to predict a poorer prognosis in breast cancer than tumors with luminal features (26), and is differentially expressed in invasive”
ONCOMINE: a cancer microarray database and integrated data-mining platform. (2004, result): “We first looked at the expression of ERBB2 in breast cancer as per the study of Sorlie et al. [21].”
A Molecular Taxonomy for Urothelial Carcinoma (2012, background): “for, for example, breast cancer in which 4 main classes of tumors have been defined; luminal A, luminal B, HER2enriched, and basal-like, which show different clinical outcomes (13, 14).”
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. (2009, background): “Transcriptional profiling has defined breast cancer subtypes (8, 9).”
Breast cancer intrinsic subtype classification, clinical use and future trends. (2015, background): “Luminal A tumors have higher expression of ER-related genes and lower expression of proliferative genes than luminal B cancers [12, 14].”
Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-negative Breast Cancer (2014, background): “2), which lack expression of ER, PR, and Her2, present with higher grade, often contain mutations in TP53 (3), and have a poor prognosis (4).”
When mutants gain new powers: news from the mutant p53 field (2009, background): “Specifically, strong association was found between TP53 mutations and expression signatures that were previously demonstrated to predict patient surviva”